Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Deshwar, A; Margonis, GA; Andreatos, N; Barbon, C; Wang, J; Buettner, S; Wagner, D; Sasaki, K; Beer, A; Løes, IM; Pikoulis, E; Damaskos, C; Garmpis, N; Kamphues, K; He, J; Kaczirek, K; Poultsides, G; Lønning, PE; Mischinger, HJ; Aucejo, FN; Kreis, ME; Wolfgang, CL; Weiss, MJ.
Double KRAS and BRAF Mutations in Surgically Treated Colorectal Cancer Liver Metastases: An International, Multi-institutional Case Series.
Anticancer Res. 2018; 38(5):2891-2895
Doi: 10.21873/anticanres.12535
(- Case Report)
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Mischinger Hans-Jörg
- Wagner Doris
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- While previously believed to be mutually exclusive, concomitant mutation of Kirsten rat sarcoma viral oncogene homolog (KRAS)- and V-raf murine sarcoma b-viral oncogene homolog B1 (BRAF)-mutated colorectal carcinoma (CRC), has been described in rare instances and been associated with advanced-stage disease. The present case series is the first to report on the implications of concurrent KRAS/BRAF mutations among surgically treated patients, and the largest set of patients with surgically treated colorectal liver metastasis (CRLM) and data on KRAS/BRAF mutational status thus far described. We present cases from an international, multi-institutional cohort of patients that underwent hepatic resection for CRLM between 2000-2015 at seven tertiary centers. The incidence of KRAS/BRAF mutation in patients with CRLM was 0.5% (4/820). Of these cases, patient 1 (T2N1 primary, G13D/V600E), patient 2 (T3N1 primary, G12V/V600E) and patient 3 (T4N2 primary, G13D/D594N) succumbed to their disease within 485, 236 and 79 days respectively, post-hepatic resection. Patient 4 (T4 primary, G12S/G469S) was alive 416 days after hepatic resection. The present case series suggests that the incidence of concomitant KRAS/BRAF mutations in surgical cohorts may be higher than previously hypothesized, and associated with more variable survival outcomes than expected. Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Adenocarcinoma - genetics
- Adenocarcinoma - secondary
- Adenocarcinoma - surgery
- Aged -
- Colorectal Neoplasms - genetics
- Colorectal Neoplasms - pathology
- Colorectal Neoplasms - surgery
- Female -
- Humans -
- Liver Neoplasms - genetics
- Liver Neoplasms - secondary
- Liver Neoplasms - surgery
- Male -
- Middle Aged -
- Mutation -
- Proto-Oncogene Proteins B-raf - genetics
- Proto-Oncogene Proteins p21(ras) - genetics
- Find related publications in this database (Keywords)
- KRAS
- BRAF
- mutation
- CRLM